TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30126714

Group type: EXPERIMENTAL
Intervention: Usual instructions plus a three-minute card with language-specific audio instructions
Number of subjects: 83

Group type: COMPARATOR
Intervention: Usual discharge instructions
Number of subjects: 83
Study: 29747366

Group type: EXPERIMENTAL
Intervention: Proming(®)Toric IOL (Model: AT1BH‐AT6BH)
Number of subjects: 121

Group type: COMPARATOR
Intervention: AcrySof(®)IQ Toric IOL (Model: SN6AT2‐SN6AT7)
Number of subjects: 121
Study: 28721298

Group type: EXPERIMENTAL
Intervention: Single IM hydrocortisone sodium succinate injection plus ordinary post‐operative treatment
Number of subjects: 117

Group type: COMPARATOR
Intervention: Post‐operative treatment alone
Number of subjects: 117
Study: 26180028

Group type: EXPERIMENTAL
Intervention: LNG-IUS
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cu-IUD
Number of subjects: 100
Study: 23126367

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (200 ml thrice daily for 4 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 10
Study: 20947384

Group type: EXPERIMENTAL
Intervention: Sirolimus (SIR) based immunosuppressive regimen
Number of subjects: 181

Group type: COMPARATOR
Intervention: Tacrolimus (TAC)/azathioprine (AZA)/prednisone immunosuppressive regimen
Number of subjects: 181
Study: 19027432

Group type: EXPERIMENTAL
Intervention: Home-based behavioral treatment emphasizing problem solving and activity scheduling
Number of subjects: 64
Study: 17135988

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Combined treatment (Fluoxetine + CBT)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Clinical management with pill placebo
Number of subjects: 439
Study: 14514569

Group type: EXPERIMENTAL
Intervention: Pravastatin therapy, 40 mg/day over 6.0 years
Number of subjects: 2017

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2017
Study: 10919939

Group type: EXPERIMENTAL
Intervention: Low-glycemic-index breakfast cereal
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: High-glycemic-index breakfast cereal
Number of subjects: 91

Group type: COMPARATOR
Intervention: Monounsaturated fatty acids (MUFA)
Number of subjects: 91
Study: 9285143

Group type: EXPERIMENTAL
Intervention: Urinary IgG excretion
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low serum albumin and transferrin, high urinary transferrin, beta-microglobulin, and IgG excretion
Number of subjects: 22
Study: 8360131

Group type: EXPERIMENTAL
Intervention: Amikacin 15 mg/kg/day given as a single dose (once-daily)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Amikacin 15 mg/kg/day given in two divided doses at 12 h intervals (twice-daily)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Both regimens (once-daily and twice-daily)
Number of subjects: 316
Study: 3526986

Group type: EXPERIMENTAL
Intervention: one inhalation isoetharine mesylate (IM)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: two inhalations isoetharine mesylate (IM)
Number of subjects: 19

Group type: COMPARATOR
Intervention: one inhalation placebo (P)
Number of subjects: 19

Group type: COMPARATOR
Intervention: two inhalations placebo (P)
Number of subjects: 19
Study: 29803986

Group type: EXPERIMENTAL
Intervention: High-dose autologous bone marrow mononuclear cells (200 million cells)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study: 26837471

Group type: EXPERIMENTAL
Intervention: Human diploid cell‐based inactivated EV71 vaccine
Number of subjects: 12000
Study: 24103146

Group type: EXPERIMENTAL
Intervention: Patient informed consent documents
Number of subjects: 9
Study: 23678500

Group type: EXPERIMENTAL
Intervention: Screening strategy including body measurements, medical interviews, and seven group educational sessions.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adapted care management conducted inside schools.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimizing waiting time between the three steps of the screening strategy.
Number of subjects: 0
Study: 20102428

Group type: EXPERIMENTAL
Intervention: School-based psychosocial intervention
Number of subjects: 325
Study: 19021282

Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 208

Group type: COMPARATOR
Intervention: Iopromide
Number of subjects: 208
Study: 17313873

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) 0.5 mg daily for at least 52 weeks
Number of subjects: 519

Group type: COMPARATOR
Intervention: Lamivudine (LVD) 100 mg daily for at least 52 weeks
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 519

Group type: COMPARATOR
Intervention: Lamivudine (LVD)
Number of subjects: 519
Study: 12822852

Group type: EXPERIMENTAL
Intervention: Videoconferencing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Face-to-face
Number of subjects: 20
Study: 10937502

Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 680

Group type: COMPARATOR
Intervention: Conventional treatment group
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 680
Study: 8590144

Group type: EXPERIMENTAL
Intervention: Combination therapy of 3 x 600 mg bismuth subsalicylate and 2 x 1000 mg amoxycillin
Number of subjects: 113

Group type: COMPARATOR
Intervention: Bismuth subsalicylate monotherapy
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Cured of H. pylori infection
Number of subjects: 113

Group type: COMPARATOR
Intervention: H. pylori-positive after treatment
Number of subjects: 113
Study: 2665761

Group type: EXPERIMENTAL
Intervention: Selective digestive decolonization (SDD) with non-resorbable antibiotics: 4 x 100 mg of polymyxin B, 4 x 500 mg of amphotericin B, and 4 x 80 mg of tobramycin via gastric tube.
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Selective digestive decolonization (SDD) with non-resorbable antibiotics.
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no SDD treatment).
Number of subjects: 102
Study: 922398

Group type: EXPERIMENTAL
Intervention: Preoperative reassurance about anaesthesia from a member of the hospital staff
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reading a booklet designed to reassure about anaesthesia
Number of subjects: 0
Study: 30967655

Group type: EXPERIMENTAL
Intervention: Early transpyloric feeding (TPF)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Gastric feeding
Number of subjects: 368
Study: 28917360

Group type: EXPERIMENTAL
Intervention: Acupressure at LIV3
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acupressure at LI4
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo points
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acupressure (LIV3 or LI4)
Number of subjects: 90
Study: 26337249

Group type: EXPERIMENTAL
Intervention: Increase in waist circumference (WC) over 6 years
Number of subjects: 2492

Group type: EXPERIMENTAL
Intervention: Normal weight women at baseline and ever-smokers
Number of subjects: 2492
Study: 23527522

Group type: EXPERIMENTAL
Intervention: Mindfulness training during a 3-month meditation retreat
Number of subjects: 57
Study: 21886949

Group type: EXPERIMENTAL
Intervention: Upper Body Resistance Training (UBRT) for 4 weeks, 3 times weekly
Number of subjects: 30

Group type: COMPARATOR
Intervention: Breathing exercise for 10 min (Control Group)
Number of subjects: 30
Study: 17687267

Group type: EXPERIMENTAL
Intervention: Combined muscarinic antagonist (glycopyrrolate, GLY) and alpha‐2 agonist (dexmedetomidine, DEX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimethaphan (TMP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study: 17023709

Group type: EXPERIMENTAL
Intervention: Rice-based lunch meal fortified with 20 mg Fe as micronized ground ferric pyrophosphate (MGFP)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control meal (unfortified rice-based lunch)
Number of subjects: 184
Study: 14750577

Group type: EXPERIMENTAL
Intervention: Prednisolone (40 mg/day for 16 weeks)
Number of subjects: 815

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: None (TB monitoring)
Number of subjects: 815
Study: 11279319

Group type: EXPERIMENTAL
Intervention: PTCA (Percutaneous Transluminal Coronary Angioplasty)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: PTCA (1 month follow-up)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: PTCA (6 months follow-up)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 48
Study: 9499603

Group type: EXPERIMENTAL
Intervention: Digital imaging and teledermatology
Number of subjects: 0
Study: 8232372

Group type: EXPERIMENTAL
Intervention: Anticoagulation with warfarin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Platelet inhibitor therapy with aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3080292

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms qid
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Misoprostol 300 micrograms qid
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study: 31121365

Group type: EXPERIMENTAL
Intervention: High sensitivity C-reactive protein (HsCRP) on day 3
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High sensitivity C-reactive protein (HsCRP) on day 8
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Interleukin‐6, vascular cell adhesion molecule‐1, intercellular adhesion molecule‐1, interleukin‐8, interleukin‐10, interferon gamma, and tumor necrosis factor alpha
Number of subjects: 90
Study: 29027598

Group type: EXPERIMENTAL
Intervention: Paclitaxel 80 mg/m2 plus pelareorep 3 × 10^10 TCID50
Number of subjects: 74

Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 74
Study: 26741286

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT) administration (40 IU)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 25421781

Group type: EXPERIMENTAL
Intervention: Telephone-delivered physical activity intervention (pedometers and eight weekly phone calls)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (written information regarding physical activity)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study: 23020794

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54519
Study: 20616686

Group type: EXPERIMENTAL
Intervention: 350-microg dexamethasone DDS
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 700-microg dexamethasone DDS
Number of subjects: 80

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 80
Study: 18823000

Group type: EXPERIMENTAL
Intervention: Web-based, self-guided alcohol treatment program
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 44
Study: 15691345

Group type: EXPERIMENTAL
Intervention: Brushing with dentifrice
Number of subjects: 79

Group type: COMPARATOR
Intervention: Brushing without dentifrice
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Self-brushing (with dentifrice)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Professional brushing (with dentifrice)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Brushing with dentifrice (self-brushing) vestibular surfaces
Number of subjects: 79

Group type: COMPARATOR
Intervention: Brushing with dentifrice (professional brushing) vestibular surfaces
Number of subjects: 79
Study: 11888048

Group type: EXPERIMENTAL
Intervention: Nurse-managed minimal-contact smoking cessation intervention
Number of subjects: 388

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 388
Study: 10765007

Group type: EXPERIMENTAL
Intervention: Intensive therapy (INT)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Standard therapy (STD)
Number of subjects: 153
Study: 7568598

Group type: EXPERIMENTAL
Intervention: Innovative prenatal program
Number of subjects: 116

Group type: COMPARATOR
Intervention: Traditional prenatal education program
Number of subjects: 116
Study: 1892240

Group type: EXPERIMENTAL
Intervention: Impedance cardiography
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pulsed Doppler echocardiography
Number of subjects: 0
Study: 6881256

Group type: EXPERIMENTAL
Intervention: Sensory integrative activities
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sedentary activities (Control)
Number of subjects: 7
Study: 31289018

Group type: EXPERIMENTAL
Intervention: 3D-OFDI guidance
Number of subjects: 106

Group type: COMPARATOR
Intervention: Angiography guidance
Number of subjects: 106
Study: 31240870

Group type: EXPERIMENTAL
Intervention: 37.5-minute rTMS protocol
Number of subjects: 30

Group type: COMPARATOR
Intervention: 18.75-minute rTMS protocol
Number of subjects: 30
Study: 30076982

Group type: EXPERIMENTAL
Intervention: Standard advice plus personalised air-quality feedback (Group B)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard health service advice on SHS (Group A)
Number of subjects: 120
Study: 27136447

Group type: EXPERIMENTAL
Intervention: Metformin and acupuncture combined therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin monotherapy
Number of subjects: 0
Study: 25174484

Group type: EXPERIMENTAL
Intervention: 2 U batroxobin
Number of subjects: 240

Group type: COMPARATOR
Intervention: 50 mg mannitol
Number of subjects: 240
Study: 21915641

Group type: EXPERIMENTAL
Intervention: Inhibitory conditioned stimulus (CS) presented nonreinforced
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibitory conditioned stimulus (CS) presented extended
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subsequent presentations of the inhibitory CS with a novel CS
Number of subjects: 0
Study: 19952822

Group type: EXPERIMENTAL
Intervention: 2 mg x kg(−1) caffeine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 4 mg x kg(−1) caffeine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 6 mg x kg(−1) caffeine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 18164275

Group type: EXPERIMENTAL
Intervention: Variable lighting conditions (500-1800 lx, 6500 K; 500 lx, 4000 K)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular light
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Variable light
Number of subjects: 0
Study: 16485864

Group type: EXPERIMENTAL
Intervention: Frailty Index based on Comprehensive Geriatric Assessment (FI-CGA)
Number of subjects: 2305
Study: 12017516

Group type: EXPERIMENTAL
Intervention: Specific ADL observations
Number of subjects: 106

Group type: COMPARATOR
Intervention: Barthel ADL Index
Number of subjects: 106
Study: 9920950

Group type: EXPERIMENTAL
Intervention: Twice-daily thoracic radiotherapy (45 Gy over three weeks)
Number of subjects: 417

Group type: COMPARATOR
Intervention: Once-daily thoracic radiotherapy (45 Gy over five weeks)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Twice-daily thoracic radiotherapy
Number of subjects: 417

Group type: COMPARATOR
Intervention: Once-daily thoracic radiotherapy
Number of subjects: 417
Study: 7731455

Group type: EXPERIMENTAL
Intervention: Intraportal infusion of 5-fluorouracil (500mg per day) for 14 days from 21 postoperative days and lipiodol-aclarubicin (40mg) at 35 POD
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (hepatectomy alone)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Intraportal infusion of 5-fluorouracil and lipiodol-aclarubicin
Number of subjects: 55
Study: 1665176

Group type: EXPERIMENTAL
Intervention: Lisinopril-Hydrochlorothiazide 20 mg/12.5 mg
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Lisinopril-Hydrochlorothiazide 20 mg/25 mg
Number of subjects: 603

Group type: COMPARATOR
Intervention: Lisinopril 20 mg
Number of subjects: 603

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 12.5 mg
Number of subjects: 603
Study: 7378250

Group type: EXPERIMENTAL
Intervention: Isoprenaline infusion intravenously at different rates
Number of subjects: 0
Study: 31462252

Group type: EXPERIMENTAL
Intervention: Large plate
Number of subjects: 134

Group type: COMPARATOR
Intervention: Small plate
Number of subjects: 134
Study: 28077507

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 21105
Study: 26193882

Group type: EXPERIMENTAL
Intervention: Individualised physical activity on prescription (PAP) for 6 months
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 101
Study: 23609927

Group type: EXPERIMENTAL
Intervention: Multidisciplinary structured intervention (6 sessions)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 131
Study: 22909927

Group type: EXPERIMENTAL
Intervention: Religion-based tobacco control intervention (pamphlet describing health effects and rabbinical prohibitions on smoking)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Control group (schools without enforced smoking regulations)
Number of subjects: 340
Study: 20212249

Group type: EXPERIMENTAL
Intervention: DD 9 microg/kg/d
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: DD 18 microg/kg/d
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: DD (both doses)
Number of subjects: 144
Study: 18035198

Group type: EXPERIMENTAL
Intervention: Fluvastatin (20, 40, and 80 mg daily)
Number of subjects: 7043

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 7043
Study: 15727648

Group type: EXPERIMENTAL
Intervention: Altoderm lotion (4% sodium cromoglicate)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Altoderm lotion
Number of subjects: 114
Study: 12243916

Group type: EXPERIMENTAL
Intervention: Prehospital fibrinolysis (n=419) with accelerated alteplase
Number of subjects: 840
Study: 9840118

Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic acid (500 mg or 750 mg daily for 6 months)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 8302553

Group type: EXPERIMENTAL
Intervention: Fluorescein solution (5 microliters) administered under the upper lid
Number of subjects: 2

Group type: COMPARATOR
Intervention: Fluorescein solution (5 microliters) administered under the lower lid
Number of subjects: 2
Study: 2454783

Group type: EXPERIMENTAL
Intervention: Early intervention program consisting of 11 sessions over a 3-month period.
Number of subjects: 82

Group type: COMPARATOR
Intervention: Low-birthweight (LBW) control group (no intervention).
Number of subjects: 82

Group type: COMPARATOR
Intervention: Normal birthweight (NBW) control group (no intervention).
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: LBW experimental group (early intervention).
Number of subjects: 82
Study: 29189044

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (25-50 mg/d)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/d)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339
Study: 27535313

Group type: EXPERIMENTAL
Intervention: Sleep Hygiene Awareness and Practice Scale (SHAPS)
Number of subjects: 194
Study: 24761877

Group type: EXPERIMENTAL
Intervention: Glycididazole sodium (CMNa) 800 mg/m2 before radiotherapy, administered by intravenous drip, three times a week
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Glycididazole sodium (CMNa)
Number of subjects: 91
Study: 23749007

Group type: EXPERIMENTAL
Intervention: Ultracision (UC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Electrocautery (EC)
Number of subjects: 40
Study: 19755476

Group type: EXPERIMENTAL
Intervention: PU- dialysis membrane
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PU+ dialysis membrane
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Haemodiafiltration
Number of subjects: 8

Group type: COMPARATOR
Intervention: Haemodialysis
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Haemodiafiltration with PU+
Number of subjects: 8
Study: 18980082

Group type: EXPERIMENTAL
Intervention: Mitral balloon valvuloplasty (MBV)
Number of subjects: 531
Study: 16184835

Group type: EXPERIMENTAL
Intervention: Varicose veins wall
Number of subjects: 26
Study: 14513923

Group type: EXPERIMENTAL
Intervention: Current smokers (abstinent)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current smokers (non-abstinent)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ex-smokers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Never-smokers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Masked exposure condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ex-smokers and never-smokers
Number of subjects: 0
Study: 10548192

Group type: EXPERIMENTAL
Intervention: Clinical practice guidelines (Phase II)
Number of subjects: 321
Study: 8752611

Group type: EXPERIMENTAL
Intervention: Continuous oral contraceptive therapy (30 micrograms ethinyl E2 plus 150 micrograms desogestrel)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cyclic oral contraceptive therapy
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist (GnRH-a, leuprolide acetate depot 3.75 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Continuous oral contraceptive therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone agonist (GnRH-a)
Number of subjects: 14
Study: 1790313

Group type: EXPERIMENTAL
Intervention: Freeze-dried sodium phenytoin-milk formulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capsule formulation administered with water or milk
Number of subjects: 0
Study: 6846435

Group type: EXPERIMENTAL
Intervention: 1 gm of calcium per day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2 gm of calcium per day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 31828170

Group type: EXPERIMENTAL
Intervention: Kaolin-impregnated gauze
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard sterilized dry gauze (control group)
Number of subjects: 26
Study: 29560937

Group type: EXPERIMENTAL
Intervention: Submaximal doses of mexidol (750 mg infusion in 250 ml of 0.9% NaCl solution for 6 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 60
Study: 26764419

Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 23
Study: 24630753

Group type: EXPERIMENTAL
Intervention: Eplerenone (n=3319)
Number of subjects: 6632

Group type: COMPARATOR
Intervention: Placebo (n=3313)
Number of subjects: 6632
Study: 22469232

Group type: EXPERIMENTAL
Intervention: Wii‐IVR (interactive virtual reality Wii)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional GDH rehabilitation (control group)
Number of subjects: 30